Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

BeiGene Approved to Start China Phase of Global BTK-Inhibitor Trial

publication date: Mar 8, 2016
BeiGene, a Beijing novel oncology drug development company, received CFDA approval of its Clinical Trial Application for BGB-3111, a BTK inhibitor intended to treat B-cell malignancies. Previously, BeiGene has begun trials of the molecule in Australia and the US. BeiGene believes BGB-3111 is more selective than AbbVie's (NYSE: ABBV) Imbruvica (ibrutinib), which is expected to generate $1 billion of revenue this year. In December, BeiGene reported positive early results from the Australian trial of BGB-3111. More details....

Stock Symbol: (NSDQ: BGNE)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital